CNS Pharmaceuticals, Inc. Increase (Decrease) in Accounts Payable, Related Parties
CNS Pharmaceuticals, Inc. (CNSP) reported Increase (Decrease) in Accounts Payable, Related Parties of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-03.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties · last filed 2022-03-03
- CNS Pharmaceuticals, Inc. increase (decrease) in accounts payable, related parties for the quarter ending 2021-12-31 was $0.00.
- CNS Pharmaceuticals, Inc. increase (decrease) in accounts payable, related parties for the quarter ending 2021-09-30 was $0.00.
- CNS Pharmaceuticals, Inc. increase (decrease) in accounts payable, related parties for the quarter ending 2021-06-30 was $0.00.
- CNS Pharmaceuticals, Inc. increase (decrease) in accounts payable, related parties for the quarter ending 2021-03-31 was $0.00, a 100.00% decline year-over-year.
- CNS Pharmaceuticals, Inc. increase (decrease) in accounts payable, related parties for fiscal 2021 was $0.00.
- CNS Pharmaceuticals, Inc. increase (decrease) in accounts payable, related parties for fiscal 2020 was -$45.83K, a 201.76% decline from fiscal 2019.
- CNS Pharmaceuticals, Inc. increase (decrease) in accounts payable, related parties for fiscal 2019 was $45.04K.
- CNS Pharmaceuticals, Inc. increase (decrease) in accounts payable, related parties for fiscal 2018 was -$14.21K.
| Period end | Increase (Decrease) in Accounts Payable, Related Parties 3 month | Increase (Decrease) in Accounts Payable, Related Parties 6 month | Increase (Decrease) in Accounts Payable, Related Parties 9 month | Increase (Decrease) in Accounts Payable, Related Parties 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $0.00 derived: sum of 2 quarters · filed 2022-03-03 | $0.00 derived: sum of 3 quarters · filed 2022-03-03 | $0.00 10-K · filed 2022-03-03 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $0.00 derived: sum of 2 quarters · filed 2021-11-12 | $0.00 10-Q · filed 2021-11-12 | $0.00 derived: sum of 4 quarters · filed 2022-03-03 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $0.00 10-Q · filed 2021-08-13 | $0.00 derived: sum of 3 quarters · filed 2022-03-03 | $0.00 derived: sum of 4 quarters · filed 2022-03-03 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-13 | $0.00 derived: sum of 2 quarters · filed 2022-03-03 | $0.00 derived: sum of 3 quarters · filed 2022-03-03 | -$50.00K derived: sum of 4 quarters · filed 2022-03-03 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $0.00 derived: sum of 2 quarters · filed 2022-03-03 | -$50.00K derived: sum of 3 quarters · filed 2022-03-03 | -$45.83K 10-K · filed 2022-03-03 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$50.00K derived: sum of 2 quarters · filed 2021-11-12 | -$45.83K 10-Q · filed 2021-11-12 | -$10.00K derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | -$50.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | -$45.83K 10-Q · filed 2021-08-13 | -$10.00K derived: sum of 3 quarters · filed 2021-08-13 | |
| 2020-03-31 | $4.17K 10-Q · filed 2021-05-13 | $40.00K derived: sum of 2 quarters · filed 2021-05-13 | ||
| 2019-12-31 | $35.83K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $45.04K 10-K · filed 2021-02-12 | ||
| 2019-09-30 | $9.21K 10-Q · filed 2019-12-20 | |||
| 2018-12-31 | $794.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$14.21K 10-K · filed 2020-03-12 | ||
| 2018-09-30 | -$15.00K 10-Q · filed 2019-12-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |